Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Extracellular-Matrix-Based Materials from Decellularized Tissue: Opportunities, Challenges, and Future Directions in Regenerative Medicine

Laude M., Kolliopoulos V., Mikos AG., White LJ., Cosgriff-Hernandez E.

Narrative Review on Cardiovascular Disease, published in Adv Healthc Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Adv Healthc Mater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41243578
PMCID
PMC12790312
DOI
10.1002/adhm.202502107
Citations
8

Abstract (original English)

Extracellular matrix (ECM) biomaterials have been used as inductive scaffolds to promote tissue regeneration in a variety of clinical applications. ECM biomaterials derived from decellularized tissue (dECM) can retain essential bioactive components of the native ECM that can guide cellular processes; however, the composition and bioactivity of the dECM is highly dependent on the decellularization and postprocessing methods. This intrinsic regenerative potential underpins the clinical success of dECM biomaterials in applications including soft tissue repair, cardiac reconstruction, and urological interventions. Here, clinical use of current dECM biomaterials, advances in the fabrication of dECM biomaterials, and hurdles to clinical translation of dECM products are discussed. Clinical use to date has mostly been limited to native dECM sheets or milling to generate powder dECM. Recent advances in fabrication methods from electrospinning to 3D printing have expanded the potential clinical applications of dECM biomaterials by increasing the structural and compositional complexity available to researchers. Despite significant progress, challenges remain in standardizing decellularization processes, optimizing dECM bioactivity retention, and ensuring mechanical compatibility with native tissues. Future research should focus on refining fabrication techniques and establishing standardi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Extracellular MatrixAnimalsHumansBiocompatible MaterialsTissue EngineeringRegenerative MedicineTissue ScaffoldsDecellularized Extracellular Matrix

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research